Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/4/23 Free

Executive/Senior Manager

400,000 0.6684%
1/2/23 Free

Chief Technology Officer

400,000 0.6686%
1/2/23 Free

Chief Operating Officer

400,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
+3.31%-3.70%+61.03%+103.64% 70.64B
-0.11%+0.47%+50.38%+92.97% 66.11B
-1.03%+0.46%+8.14%-5.28% 27.98B
-2.41%-2.95%-9.77%+455.82% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
+1.02%+6.43%+269.42%+420.34% 20.4B
+0.65%+1.35%+35.19%-17.11% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-1.50%+2.92%+43.50%+151.30% 13.69B
Average -1.51%+0.99%+59.38%+193.88% 31.99B
Weighted average by Cap. +0.43%+0.65%+56.60%+154.61%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock